Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emili Montserrat

Showing results (21-30 of 184) with videos related to

Pageof 19
Sort By:
Molecular Medicine (Cambridge, Mass.)|August 24, 2018
Critical molecular pathways in CLL therapyGerardo Ferrer, Emili Montserrat
Current Opinion in Oncology|August 29, 2009
Genetic lesions in chronic lymphocytic leukemia: clinical implicationsEmili Montserrat, Carol Moreno
Clinical Lymphoma, Myeloma & Leukemia|August 14, 2016
Treatment of Chronic Lymphocytic Leukemia With del(17p)/TP53 Mutation: Allogeneic Hematopoietic Stem Cell Transplantation or BCR-Signaling Inhibitors?Emili Montserrat, Peter Dreger
The Lancet. Haematology|August 30, 2016
Maintenance therapy in chronic lymphocytic leukaemiaJulio Delgado, Emili Montserrat
Haematologica|January 13, 2010
Genetic lesions in chronic lymphocytic leukemia: what's ready for prime time use?Carol Moreno, Emili Montserrat
Blood Reviews|May 2, 2008
New prognostic markers in chronic lymphocytic leukemiaCarol Moreno, Emili Montserrat
Current Hematologic Malignancy Reports|February 6, 2015
Where does allogeneic stem cell transplantation fit in the treatment of chronic lymphocytic leukemia?Peter Dreger, Emili Montserrat, , et al.
Cancer|August 6, 2019
Predicting the outcome of patients with chronic lymphocytic leukemia: Progress and uncertaintyEmili Montserrat, Robert Peter Gale
Blood|June 11, 2011
Autografting CLL: the game is over!Emili Montserrat, John G Gribben
Blood|December 25, 2012
Coming full circle: 70 years of chronic lymphocytic leukemia cell redistribution, from glucocorticoids to inhibitors of B-cell receptor signalingJan A Burger, Emili Montserrat
Pageof 19

Showing results (21-30 of 184) with videos related to

Sort By:
Pageof 19
Molecular Medicine (Cambridge, Mass.)|August 24, 2018
Critical molecular pathways in CLL therapyGerardo Ferrer, Emili Montserrat
Current Opinion in Oncology|August 29, 2009
Genetic lesions in chronic lymphocytic leukemia: clinical implicationsEmili Montserrat, Carol Moreno
Clinical Lymphoma, Myeloma & Leukemia|August 14, 2016
Treatment of Chronic Lymphocytic Leukemia With del(17p)/TP53 Mutation: Allogeneic Hematopoietic Stem Cell Transplantation or BCR-Signaling Inhibitors?Emili Montserrat, Peter Dreger
The Lancet. Haematology|August 30, 2016
Maintenance therapy in chronic lymphocytic leukaemiaJulio Delgado, Emili Montserrat
Haematologica|January 13, 2010
Genetic lesions in chronic lymphocytic leukemia: what's ready for prime time use?Carol Moreno, Emili Montserrat
Blood Reviews|May 2, 2008
New prognostic markers in chronic lymphocytic leukemiaCarol Moreno, Emili Montserrat
Current Hematologic Malignancy Reports|February 6, 2015
Where does allogeneic stem cell transplantation fit in the treatment of chronic lymphocytic leukemia?Peter Dreger, Emili Montserrat, , et al.
Cancer|August 6, 2019
Predicting the outcome of patients with chronic lymphocytic leukemia: Progress and uncertaintyEmili Montserrat, Robert Peter Gale
Blood|June 11, 2011
Autografting CLL: the game is over!Emili Montserrat, John G Gribben
Blood|December 25, 2012
Coming full circle: 70 years of chronic lymphocytic leukemia cell redistribution, from glucocorticoids to inhibitors of B-cell receptor signalingJan A Burger, Emili Montserrat
Pageof 19